Title: Associations of Genetic Variants in the Dopamine Transporter with Problematic Sexual Behavior and Reward Deficiency Syndrome

Short title: *SLC6A3* Variants and Problematic Sexual Behavior

Authors:

Shui Jiang, (shui2@ualberta.ca), PhD[1]

Jerome C. Foo, (jfoo@ualberta.ca), PhD[1,2,3]

Xiuying Hu, (xiuying@ualberta.ca), BM, MSc[4]

Leslie Roper, (ljroper1@gmail.com), MSc, MC[1]

Esther Yang, (hyunjoo@ualberta.ca), MSc[1]

Bradley Green, (BGreen@uttyler.edu), PhD[5]

Randolph Arnau, (randolph.arnau@usm.edu), PhD[6]

Behavioral Addictions Studies and Insights Consortium*,

Rohit J. Lodhi, (Rohit.Lodhi@sjhc.london.on.ca), PhD, FRANZCP, FRCPsych[1,7]

Rick Isenberg, (rickisenberg@icloud.com), MD[8]

David Wishart, (dwishart@ualberta.ca), PhD[9]

Esther Fujiwara, (efujiwar@ualberta.ca), PhD[1]

Patrick J. Carnes, (pcarnes@newfreedomcorp.com), PhD[10],

Katherine J. Aitchison, (kaitchis@ualberta.ca), BM BCh, PhD, FRCPsych[1,3,4,11]

Affiliations:

[1]Department of Psychiatry, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, AB, Canada

23 [2]Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health,
24 Mannheim, Germany
25 [3]Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada
26 [4]Department of Medical Genetics, Faculty of Medicine and Dentistry, College of Health
27 Sciences, University of Alberta, Edmonton, AB, Canada
28 [5]Department of Psychology and Counseling, University of Texas at Tyler, Tyler, TX, USA
29 [6]School of Psychology, University of Southern Mississippi, Hattiesburg, MS, USA
30 [7]Department of Psychiatry, Schulich School of Medicine and Dentistry, Western University,
31 London, ON, Canada
32 [8]Psychological Counselling Services, Scottsdale, AZ, USA
33 [9]Department of Biological Sciences, Faculty of Science, College of Natural and Applied
34 Sciences, University of Alberta, Edmonton, AB, Canada
35 [10]Gentle Path at the Meadows, Wickenburg, AZ, USA
36 [11]The Psychiatry Section, Division of Clinical Sciences, Northern Ontario School of Medicine,
37 Thunder Bay, ON, Canada
38
39 **Correspondence to:**
40 Katherine Aitchison, BM BCh, PhD, FRCPsych
41 Tel number: 780-492-4018
42 Email: kaitchis@ualberta.ca
43 5-020, Katz Group Centre for Pharmacy and Health Research, Edmonton, AB, Canada
44
45 ***Consortium authors in supplementary material**

Funding Sources:

The work herein was supported by an Alberta Centennial Addiction and Mental Health Research Chair and transitional funding (to KJA), Canada Foundation for Innovation (CFI), John R. Evans Leaders Fund (JELF) grant (32147 - Pharmacogenetic translational biomarker discovery), Alberta Innovation and Advanced Education Small Equipment Grants Program (to KJA), and a research grant and philanthropic support from the American Foundation for Addiction Research (to KJA). A Fulbright-Canada-Palix Foundation grant (to PJC) assisted with his contributions to study design, project management, and collaborative working. SJ was supported by an Alberta Innovates Postdoctoral Recruitment Fellowship.

Authors' contribution:

RI, RJL, PJC, and KJA contributed to securing funding. RI, RJL, BG, PJC, and KJA contributed to the study concept and design and ethics. RI and PJC oversaw the patient recruitment by the BASIC, supported in terms of data collection by BG and RA, and for sample collection by KJA, LR, and XH. The university participant recruitment was led by KJA, supported by LR and EY. XH and SJ contributed to the *SLC6A3* genotyping. SJ, JCF, DW, EF, and KJA contributed to data analysis, interpretation, and drafting and revising the paper.

Conflicts of interest:

While PJC was previously a Board member of the American Foundation for Addiction Research, he is no longer a member. Moreover, neither the Foundation nor any other of the funders played

68 any role in study design, or in data analysis or interpretation thereof. All other authors declare no
69 conflicts of interest.
70
71 **Ethics:**
72 All participants provided written informed consent. The Quorum Review Institutional Review
73 Board (Seattle, Washington; Protocol Number: 2016-001) and the University of Alberta
74 Research Ethics Board (Protocol: Pro00066552) approved the study.
75
76 **Abstract word count:** 244
77 **Manuscript word count (not including references, tables, or figure legends):** 3847
78 **Number of references:** 40

ABSTRACT

Objectives

Problematic sexual behavior (PSB) is defined by recurrent sexual behaviors that are difficult to control, causing social and functional impairments. PSB can co-occur with reward deficiency syndrome (RDS), but this relationship remains unclear. RDS has been associated with the 10/10 genotype of 3' variable number tandem repeat (VNTR) in the dopamine transporter gene *SLC6A3,* which is implicated in the reward pathway. This study investigates the genetic relationship between PSB and RDS, testing their association with *SLC6A3* 3' VNTR genotype.

Methods

PSB patients from addiction treatment facilities (n=454), and comparison participants (with non-clinical PSB=82; without PSB, n=888) were recruited. PSB was measured by the Sexual Addiction Screening Test-Revised (SAST-R) Core and RDS was measured using a composite variable from a custom test battery. DNA was collected from saliva and buccal swabs. Genotyping was performed using polymerase chain reaction (PCR), and regression analyses were conducted to investigate the association of *SLC6A3* 3' VNTR genotype with PSB and RDS.

Results

The 10/10 genotype of *SLC6A3* 3' VNTR was associated with RDS in a combined analysis of all groups, and with non-clinical PSB in the comparison participants. In patients, rare *SLC6A3* 3' VNTR genotypes (3-, 6-, 8-, 11-repeat alleles) were associated with PSB. No genotype showed relationships to RDS in only PSB patients.

Conclusions

The association between the 10/10 genotype and RDS in the whole sample is consistent with previous findings associating this genotype with vulnerability to addictions. Consistent with our

earlier report of PSB being related to RDS, this genotype was also associated with PSB in participants with PSB of a lesser severity. This is the first report of an association between the 10/10 genotype and PSB. In those with PSB of a greater severity, the power of the analysis was less, with a suggestive signal for an association between rare genotypes of the dopamine transporter and PSB.

Keywords: behavioral addiction; reward deficiency syndromes; genetics; dopamine transporter gene

113 **1. INTRODUCTION**

114 Problematic sexual behavior (PSB) is defined as difficult to control recurrent sexual behaviors
115 that cause social and functional impairments (S. Jiang et al., 2023). PSB can be referred to as sex
116 addiction (Carnes, 1991), or compulsive sexual behavior (Kuzma & Black, 2008). The scientific
117 debate on the nosology and nature of PSB continues, but it is recognized that PSB often co-
118 occurs with neuropsychiatric conditions such as reward deficiency syndrome (Blum et al., 2000;
119 Comings & Blum, 2000), possibly suggesting common underlying biology.

120 Reward deficiency syndrome (RDS), often described as an "octopus of behavioral
121 dysfunction," is not a single mental health condition, but a collection of conditions including
122 addictive, compulsive, and impulsive behaviors, and personality disorders, which share
123 endophenotypes characterized by hypodopaminergia in the reward circuit (Blum et al., 2022;
124 Blum et al., 2017; Gondre-Lewis et al., 2020). Although the relationship between RDS and PSB
125 is not well characterized, there is emerging evidence that they may overlap (S. Jiang et al., 2023).
126 Jiang et al. (2023) reported that compared to those without PSB, university students with PSB
127 showed significantly higher rates of conditions with known alterations in the dopaminergic
128 reward pathway which would fall under the umbrella of RDS (e.g., Attention
129 Deficit/Hyperactivity Disorder [ADHD], obsessive-compulsive disorder [OCD], and personality
130 disorders) (S. Jiang et al., 2023).

131 Addictive behaviors and symptoms are core features of RDS (Blum et al., 2024), and
132 there are several genetic variants associated with vulnerability, maintenance, and relapse in
133 addiction (Franklin et al., 2009; Ma et al., 2016; Reith et al., 2022). It is possible that at least part
134 of the phenotypic overlap between PSB and RDS may be driven by genetic variants common to
135 the two. For example, in one study, 81% of sexual addiction patients reported that at least one
136 parent had an addictive disorder, with 36% indicating that a parent had a sexual addiction

137 (Schneider & Schneider, 1996). One of the potential genetic variants for addictive disorder is the
138 dopamine transporter gene *SLC6A3* (*solute carrier family 6 member 3*), located at chromosome
139 5p15.33. There is a 40-base pair variable number tandem repeat (VNTR) in the 3' untranslated
140 region of *SLC6A3* with 9- and 10- repeat alleles being the most common (Vandenbergh, et al.,
141 1992a). Studies have shown that individuals with the *SLC6A3* 10/10 genotype express higher
142 levels of dopamine transporter than 9-repeat allele carriers, and this is reflected in lower striatal
143 dopamine among 10-repeat carriers (Dreher et al., 2009).

144 The dopamine transporter mediates the reuptake of dopamine from the synaptic cleft
145 (Vandenbergh et al., 1992b), and the 10/10 genotype of the *SLC6A3* 3' VNTR has been
146 implicated in various conditions associated with an altered reward system, including ADHD and
147 addictive disorders (Reith et al., 2022; Salatino-Oliveira et al., 2018; Volkow et al., 2011). For
148 example, Cornish et al. (2005) reported that the 10/10 genotype was associated with higher
149 ADHD symptom scores in boys (Cornish et al., 2005). A meta-analysis by Ma et al., (2016)
150 showed that individuals carrying the 10/10 genotype were 17% less likely to quit smoking
151 compared to those who was the 9-repeat alleles (Ma et al., 2016). Furthermore, a previous study
152 indicated that the 10-repeat allele of the *SLC6A3* 3' VNTR was associated with phenotypes
153 directly related to sexual behavior. In a study of men, Guo et al. (2007) reported that individuals
154 with at least one 10-repeat allele of the *SLC6A3* 3' VNTR showed an 80%-100% increase in the
155 number of sexual partners compared to those homozygous for the 9-repeat allele (Guo et al,
156 2008; Guo et al., 2007). While the 10/10 variant seems to be more consistently identified as the
157 risk genotype, some studies probing gene-environment (G×E) interactions pointed to a greater
158 sensitivity of 9-repeat carriers to environmental influences. For example, Erblich and colleagues
159 (2004) reported that after stress, carriers of the 9-repeat allele showed a cigarette craving four

160 times greater than non-carriers (Erblich et al., 2004). This contrasts with findings of potentially
161 protective effects of the 10-repeat variant under adverse environmental influences (stress or
162 childhood trauma) as seen in ADHD (Cornish et al., 2005), smoking (Ma et al., 2016), and
163 number of sexual partners (Guo et al., 2008; Guo et al., 2007). However, these complex
164 interactions have rarely been explored, and contradictory findings exist as well (Z. Jiang et al.,
165 2023b).

166 Apart from common alleles such as 9- and 10-repeat, rare genetic variants, such as 3-, 5-,
167 7- , 8-, and 11-repeats are also observed (Vandenbergh et al., 1992a). Despite their low
168 frequency and smaller contribution to population-wide heritability compared to common
169 variants, these rare variants can still significantly increase individual risk of illness due to their
170 pronounced impact on protein function or expression (Andreassen et al., 2023). A previous study
171 including 471 children with or without ADHD found that *SLC6A3* rare genotypes (8/10, 7/10 and
172 10/11) were associated with ADHD (Šerý et al., 2015). However, research on these rare
173 genotypes in candidate gene studies is limited, and these variants have often been excluded due
174 to their low frequency and the resulting small sample sizes.

175 The aim of the present study was to investigate the relationship between PSB and RDS at
176 the candidate gene level in PSB patients and in a non-clinical sample, with a focus on *SLC6A3*
177 3'VNTR genotype. We expected to extend the association between PSB and RDS that we had
178 previously reported in the non-clinical comparison participants to a clinical sample. We
179 hypothesized that the 10/10 genotype might be associated with PSB and/or with RDS.

180 **1. METHODS**

2.1. Participants

The clinical cohort comprised inpatients and outpatients receiving treatment for PSB at eight addiction treatment facilities in the United States (n=512). The recruitment of comparison participants (n=3530) was undertaken at a Canadian university as previously described (S. Jiang et al., 2023). Since the allele frequencies of the *SLC6A3* 3' VNTR are observed to vary by ethnicity (Doucette-Stamm et al., 1995), genotypic and phenotypic analyses were restricted to individuals of European ancestry (n=1434, Supplementary Material, Figure 1).

2.2. Measures

We screened for PSB with the 20-item Sexual Addiction Screening Test-Revised (SAST-R) Core (Carnes et al, 2010). We measured four addictive dimensions of PSB: relationship disturbance caused by sexual behaviors (SAST-R Core items 6, 8, and 16, and we also included item 26 from the additional SAST-R subscales (Carnes et al, 2010), loss of control despite problems (SAST-R Core items 10, 12, 15, and 17), preoccupation about sex (SAST-R Core items 3, 18, 19 and 20), and affect disturbance (such as anxiety and depression related to sexual behaviors, SAST-R Core items 4, 5, 11, 13 and 14). Each question is responded to with a binary choice (yes/no=1/0), and the threshold for screening positive for PSB in the general population is 6 (Carnes et al, 2010). The PSB variable we used in all analyses (referred to as the "adjusted SAST-R Core") was the scale total minus the first two questions, which inquire about a history of childhood sexual trauma and parental trouble with sexual behavior, as previously described (S. Jiang et al., 2023). These items were excluded due to their overlap with other variables in our analysis, such as "self-reported childhood trauma" and "family history of PSB." This approach was taken to avoid

202 redundancy and increase the specificity of the PSB regression, even though there are a part of
203 SAST-R Core.

204 To derive our RDS measure, several relevant conditions were assessed, including
205 nicotine dependence (Fagerström Test for Nicotine Dependence [FTND]), pathological gambling
206 (DSM-5 Pathological Gambling Diagnostic Form [DPGDF]), personality disorders (8-item
207 Standardized Assessment of Personality-Abbreviated Scale as a Self-Administered Screening
208 Test [SA-SAPAS]), ADHD (Adult ADHD Self-Report Scale [ASRS] version 1.1), compulsive
209 buying (Richmond Compulsive Buying Scale [RCBS]), and internet addiction (Internet
210 Addiction Test [IAT]), as previously described (S. Jiang et al., 2023). To represent the overall
211 RDS construct, a dummy coded binary variable was created (1=positive screening in any of the
212 RDS components, 0=no). In addition, we collected self-reported information about demographic
213 details, childhood trauma (self-reported childhood physical, emotional and sexual trauma, and
214 family history of domestic violence, combined with item 1 from the SAST-R Core "sexually
215 abused as a child", 1=yes, 0=no, as previously described (S. Jiang et al., 2023)), past or current
216 mental health diagnoses (1=yes, 0=no), number of past or current mental health diagnoses, and
217 number of mental health condition(s) in the family history. A positive family history of PSB
218 (1=yes, 0=no) was ascertained through item 2 of the SAST-R Core ("parental problems with
219 sexual behavior") and self-report data, as previously described (S. Jiang et al., 2023). Since OCD
220 in particular is reported to be associated with PSB (S. Jiang et al., 2023) and RDS (Blum et al.,
221 2000), we also used available data from MINI-International Neuropsychiatric Interview (MINI),
222 in combination with self-reported past/current OCD diagnoses to estimate rates of OCD.

223 **2.3. Procedures**

224 DNA was extracted from saliva using Oragene OG-500 kits (DNAGenotek, Kanata, Canada)
225 and/or from buccal swabs (Isohelix via D-Mark Biosciences, Toronto, Canada). Genotyping of
226 the 40 bp *SLC6A3* 3' VNTR was performed by a polymerase chain reaction (PCR). DNA was
227 amplified with an initial denaturation step at 95°C for 2 minutes, followed by 35 cycles of
228 denaturation at 95°C for 15 seconds, annealing at 64°C for 30 seconds, extension at 72°C for 1
229 minute, and a terminal extension step of 72°C for 5 minutes (modified from Vandenbergh et al.,
230 1992) (Vandenbergh et al., 1992a). The primer sequences were: forward 5'-
231 TGTGGTGTAGGGAACGGCCTGAG-3', and reverse 5-
232 CTTCCTGGAGGTCACGGCTCAAGG-3' (Vandenbergh et al., 1992a). PCRs were resolved on
233 a 2.25% agarose gel. The 9-repeat number was at 440 bp and the 10-repeat number was at 480 bp
234 on the gel; genotypes other than 9/9, 9/10, or 10/10 are considered rare genotypes (Vandenbergh
235 et al., 1992a). Since the allele frequencies of the *SLC6A3* 3' VNTR vary by ethnicity (Doucette-
236 Stamm et al., 1995), genotypic and phenotypic analyses were conducted in only those of
237 European ancestry.

238 2.4. Statistical analysis

239 Data were analyzed using STATA (StataCorp, 2023). To examine the association of PSB,
240 participants were categorized into three groups: (1) PSB patients (n = 405; patients who scored
241 ≥11 on the unadjusted SAST-R Core); (2) Comparison participants with PSB ("non-clinical"
242 PSB) (n=85) scoring ≥6 on the unadjusted SAST-R Core (Carnes et al., 2010), and (3)
243 Comparison participants without PSB (n=439) scoring <6 on the unadjusted SAST-R Core and
244 also screening negative on other relevant measurements (Carnes et al., 2010).
245 In the final analysis of PSB, a total of 929 participants (405 from the patient group and
246 524 from the comparison group) were included, after the removal of 59 individuals who were not

247 of European ancestry or did not provide DNA. The SAST-R Core, developed based on a large
248 clinical cohort (665 men and 274 women) of inpatients and outpatients in treatment for PSB,
249 classifies individuals at a cut-point of 6, achieving a sensitivity of 0.817 and specificity of 0.778
250 (Carnes et al., 2010; Giordano et al., 2024). However, to enhance the specificity of the genetic
251 association study, we selected a cut-off score of 11 on the SAST-R Core to focus on individuals
252 with more pronounced PSB symptoms. This stricter threshold was implemented to ensure clearer
253 signals for the genetic analysis by minimizing ambiguous cases, thereby prioritizing the
254 identification of true positives over the risk of false negatives. Thus, we excluded 19 patients
255 who scored <11 on the unadjusted SAST-R Core. In addition, to enhance the specificity of
256 testing for associations with PSB, we excluded a total of 432 participants who screened negative
257 for PSB, but positive for RDS or mental health conditions(s). This was done due to the
258 consideration of potentially shared genetic etiologies between RDS, PSB, and mental health
259 conditions. For the validation of RDS, all available data from patients (n=376) and comparison
260 participants (n=668) were included.

261 2.4.1. Descriptive statistics

262 To investigate if those with or without PSB have different clinical and demographic features,
263 group differences were examined with Pearson's χ^2 test or a Mann-Whitney *U* test or a Kruskal-
264 Wallis test, followed by Dunn's test. To test if the distribution of *SLC6A3* genotype differed
265 between different groups, Pearson's χ^2 was conducted. Tetrachoric (for binary variables) and
266 Kendall's τ (for ordinal variables) correlations were used to examine the correlation of clinical
267 and demographic variables with severity of PSB.

268 2.4.2. Regression analyses

269 To investigate the association of demographic and clinical variables with PSB and RDS,
270 backward stepwise logistic regressions were performed. Regarding PSB, two regression models
271 were performed: the first model included all comparison participants (with and without PSB), the
272 second model included PSB patients and comparison participants without PSB. Initial
273 independent variables in both models were: age, gender, *SLC6A3* genotype, childhood trauma,
274 self-reported mental health condition(s) (a binary variable), number of mental health condition(s)
275 in the family history (a continuous variable), and family history of PSB or of OCD. We also
276 included an interaction term of childhood trauma and *SLC6A3* genotype to test for potential G×E
277 interactions (Franke & Buitelaar, 2018; Z. Jiang et al., 2023; Lahey et al., 2011). To validate the
278 association of the 10/10 genotype with RDS, one regression model was applied using the entire
279 cohort. Initial independent variables were identical but additionally included "group"
280 (comparison participants vs. patients). Predictors were retained in the models if the model passed
281 the link test for correct specification and showed non-significant Hosmer-Lemeshow χ^2, their
282 inclusion did not introduce multicollinearity, and they remained significant in the final model. A
283 *P*-value of <0.05 was considered significant.

284 **2.5. Ethics**

285 The study procedures were carried out in accordance with the Declaration of Helsinki. All
286 participants provided written informed consent. The Quorum Review Institutional Review Board
287 (Seattle, Washington; Protocol Number: 2016-001) and the University of Alberta Research
288 Ethics Board (Protocol: Pro00066552) approved the study.

289 **3. RESULTS**

290 A total of 8.5% of comparison participants (82 out of 970) scored ≥ 6 on the unadjusted SAST-R
291 Core, meeting the threshold for PSB in the general population (Carnes et al, 2010). Patients
292 showed the highest scores in adjusted SAST-R Core and addictive dimensions of PSB ($P<0.001$,
293 Table 1). Compared to comparison participants, patients were significantly older ($P<0.001$), had
294 a higher proportion of male participants, and higher rates of RDS ($P<0.001$, Table 1).
295 Furthermore, family history of mental health condition(s) and experiencing childhood trauma
296 increased in frequency from comparison without PSB to comparison with PSB to PSB patients
297 ($P<0.001$, Table 1).

298 The distributions of *SLC6A3* genotypes (9/9, 9/10, and 10/10) were in Hardy-Weinberg
299 Equilibrium in both comparison participants and in patients (Supplementary Material, Table 1).
300 Results showed that comparison participants with the 10/10 genotype had trend level elevated
301 rates of PSB compared to 9-repeat carriers ($P=0.050$, Table 2). They also displayed significantly
302 higher RDS total scores ($P=0.0042$), especially regarding ADHD symptoms (ASRS, $P=0.021$)
303 and internet addiction (IAT, $P=0.0073$), followed by a trend level elevation in compulsive
304 buying (RCBS, $P=0.050$).

305 In comparison participants, the 10/10 genotype showed trend level correlations with RDS
306 ($\tau=0.077$, $P=0.088$), with self-reported mental health condition(s) ($\tau=0.081$, $P=0.073$), as well as
307 with PSB ($\tau=0.082$, $P=0.067$; Supplementary Material, Figure 2). In patients, however, the 10/10
308 genotype was not significantly correlated with PSB or RDS. Our results higher rates of OCD in
309 *SLC6A3* 3' VNTR rare genotype carriers ($P=0.044$, Table 2). Additional analyses on correlations
310 between genotype and SA-SAPAS items are shown in Supplementary Material, Table 2.

311 **Regression analyses**

312 In both regression models for PSB, *SLC6A3* genotype, childhood trauma, family history of PSB,
313 and gender were retained as independent variables (Model 1 in comparison participants: pseudo
314 R^2=0.12, n=509, Figure 1; Model 2 in PSB patients and comparison participants without PSB:
315 pseudo R^2=0.58, n=739, Figure 2). In Model 1, the 10/10 genotype of *SLC6A3* 3' VNTR (OR:
316 1.97, 95% confidence interval (CI): 1.15-3.38, *P*=0.013), childhood trauma (OR: 2.31, 95% CI:
317 1.21-4.41, *P*=0.011), family history of PSB (OR: 4.49, 95% CI: 1.85-10.90, *P*<0.001) and male
318 gender (OR: 4.54, 95% CI: 2.64-7.83, *P*<0.001) were associated with PSB. In Model 2, *SLC6A3*
319 3' VNTR rare genotypes (OR: 5.69, 95% CI: 1.08-30.07, *P*=0.041), childhood trauma (OR: 9.78,
320 95% CI: 4.91-19.49, *P*<0.001), family history of PSB (OR:45.65, 95% CI: 15.56-133.90,
321 *P*<0.001), and male gender (OR: 142.77, 95% CI: 52.11-391.15, *P*<0.001) were associated with
322 PSB. The 10/10 genotype was not significantly associated with PSB in model 2 (*P*=0.72). The
323 interaction term of childhood trauma and *SLC6A3* genotype was not significant in either
324 comparison participants (*P*=0.36) or in patients (*P*=0.26).

325 For RDS, the final model retained the interaction term of *SLC6A3* genotype and
326 childhood trauma, self-reported mental health condition(s), *SLC6A3* genotype, childhood trauma,
327 and group status on the entire cohort (pseudo R^2=0.13, n=1044, Figure 3). Significant parameters
328 included the 10/10 genotype of *SLC6A3* 3' VNTR (OR:2.39, 95% CI:1.52-3.77, *P*<0.001), self-
329 reported mental health condition(s) (OR:2.64, 95% CI: 1.96-3.56, *P*<0.001), childhood trauma
330 (OR:2.81, 95% CI:1.72-4.60, *P*<0.001), and being a PSB patient (OR:4.10, 95% CI:2.96-5.68,
331 *P*<0.001). The interaction term of the 10/10 genotype and childhood trauma was significantly
332 associated with decreased odds of RDS (OR:0.32, 95% CI:0.17-0.60, *P*=0.011, the detailed
333 interaction terms and predicted margins are provided in Supplementary Material, Table 3).

4. DISCUSSION AND CONCLUSION

In our study, the 10/10 genotype of the *SLC6A3* 3' VNTR was associated with PSB in healthy young adults, and with RDS across the entire cohort, suggesting that this genotype may serve as a shared genetic risk factor for both PSB and RDS. This indicated that PSB could be a manifestation of RDS in this cohort of healthy young adults. Turner et al. (2022) indicated that PSB can develop as a side effect of dopaminergic agonists in some patients with Parkinson's disease (Turner et al., 2022), aligning with our results, which aligns with our findings on the potential involvement of the dopaminergic pathway in both RDS and PSB. However, in the clinical cohort, it was rare genotypes, rather than the 10/10 genotype, that showed the association to PSB. This observation aligns with the understanding that both common and rare genetic variants can be associated with a psychiatric phenotype, with common genotypes typically exerting a smaller impact, while rare genotypes tend to have a larger impact and are associated with more severe symptoms (Andreassen et al., 2023).

Whether PSB should be regarded as a behavioral addiction or compulsive disorder remains an open question (Kraus et al., 2016; Walton & Bhullar, 2018). Of note, Koob and colleagues (2016) conceptualized addiction as a cycle with three stages, linked to disruptions in dopaminergic and serotoninergic pathways (Koob & Volkow, 2016). They further indicated that impulsivity is often seen in the early stages of addiction, and compulsivity evolves as the condition progresses (Koob & Volkow, 2016). Impulsive, reward-seeking tendencies of PSB (Kraus et al., 2016; Walton & Bhullar, 2018) could be more prominent in milder forms of PSB, such as in the comparison group, and appear to be associated with the relatively common 10/10 VNTR genotype. In contrast, the compulsive features may prevail in clinical PSB, accompanied

356 by multiple mental health comorbidities (e.g., OCD), and then be associated with rare VNTR
357 genotypes.
358 Through our convenience sampling we were not able to match comparison participants
359 and PSB patients on age and other demographic variables. These group differences could have
360 driven different manifestations of PSB, which may be associated with different genetic risk
361 factors. Riemersma et, al. (2013) proposed a "new generation of sex addiction," or
362 "comtemporary sex addiction (Riemersma & Sytsma, 2013)." While both "classical sex
363 addiction" and "contemporary sex addiction" could be assaociated with alterations in the reward
364 pathway, Riemersma et, al. (2013) suggested that "contemporary sex addiction" is primarily
365 linked to reward seeking, whereas "classical sex addiction," is predominantly associated with
366 trauma, emotional dysregulation, and insecure attachment, and may involve alterations in the
367 prefrontal and limbic regions (Riemersma & Sytsma, 2013; Schmidt et al., 2017). In our study,
368 comparison participants with PSB were significantly younger and a lower ratio of them reported
369 childhood trauma than PSB patients. Hence, the relevance of the 10/10 genotype to RDS in the
370 entire cohort might have been influenced by the larger proportion of younger participants who
371 could have had such "contemporary" PSB. In contrast, rare genotypes of the *SLC6A3* 3' VNTR,
372 higher rates of childhood trauma and mental health comorbidities such as OCD could potentially
373 be associated with more "classical" sex addiction in the clinical PSB group. Interestingly, our
374 results suggest that in patients, this VNTR may have a potential link to OCD, with those who
375 carried rare genotypes having higher rates of OCD. Some previous research has suggested a
376 potential association between this VNTR and OCD (Billett et al., 1998; Hemmingsa et al., 2003);
377 however, further studies are needed to confirm these associations. Our findings suggest that
378 treatment stratification could be advantageous; individuals with RDS-related PSB and those with

379 more severe clinical manifestations of PSB may benefit from tailored therapies that target
380 different neurological underpinnings.

381 We also investigated specific G×E interactions (*SLC6A3* 3' VNTR genotype and
382 childhood trauma) in the context of hypodopaminergic phenotypes of PSB and RDS. Although
383 such interactions have been explored in some relevant psychiatric conditions, particularly in
384 substance use, the results have been inconsistent or inconclusive (Z. Jiang et al., 2023). A
385 systematic review examining G×E between dopaminergic genes (*DRD2*, *DRD4*, and *SLC6A3*)
386 and psychological, family, and socio-demographic factors in relation to substance abuse reported
387 that five out of nine studies identified at least one significant interaction (Z. Jiang et al., 2023). In
388 the present study, we observed that the 9-repeat allele could be associated with RDS when
389 childhood trauma was present. It is possible that 9-repeat allele carriers may be more sensitive to
390 environmental influences. For example, other research has found that children with conduct
391 disorder and the 9/9 genotype showed stronger reductions in symptom severity in response to
392 both negative or positive parenting practices, compared to 10-repeat allele carriers (Lahey et al.,
393 2011).

394 This study had several limitations. The sociodemographic differences between the
395 comparison participants and patients in these convenience samples are important to
396 acknowledge; as mentioned above, age influences the phenotype and genetic susceptibility to
397 many psychiatric symptoms, presumably including PSB and RDS (Grunblatt et al., 2019;
398 Riemersma & Sytsma, 2013). Furthermore, the analysis was limited to those of European
399 ancestry and included relatively few women. Also, the sample size for rare genotypes was
400 limited, making it challenging to investigate the differential phenotypes between common and
401 rare genotypes. Additionally, only one genetic variant in the *SLC6A3* gene and only one gene in

402 the dopaminergic pathway were investigated in this study. It is possible that other genes, gene-
403 gene interactions and G×E interactions may be associated with PSB and could have impacted the
404 results. Thus, the findings should be interpreted with caution, and sample recruitment and
405 matching should be optimized in future studies. These should also incorporate a broader range of
406 common genetic variants or use a genome-wide approach, which would offer deeper insights into
407 the genetic foundations of PSB.

408 Our results suggest that both common and rare variants of *SLC6A3* may be associated
409 with PSB. The link of the 10/10 genotype to RDS suggests that PSB could be a manifestation of
410 RDS in comparison participants, whereas rare *SLC6A3* variants might be associated with clinical
411 PSB, together with comorbid mental health issues.

412

Acknowledgement:

The authors would like to express their gratitude to Dawon Lee for assisting with the study concept, design, and ethics; to Beatriz Carvalho Henriques for writing assistance with the first version of the protocol for genotyping the *SCL6A3* 3' VNTR; to May Yu for *SLC6A3* genotyping; to Pennie Carnes and Keanna Wallace for sample collection at the university; and to Dr. Diego Lapetina for laboratory management support and preliminary data analysis.

References

Andreassen, O. A., Hindley, G. F. L., Frei, O., & Smeland, O. B. (2023). New insights from the last decade of research in psychiatric genetics: discoveries, challenges, and clinical implications. *World Psychiatry, 22*(1), 4-24. https://doi.org/10.1002/wps.21034

Billett, E., Richter, M., Sam, F., Swinson, R., Dai, X.-Y., King, N., … Kennedy, J. (1998). Investigation of dopamine system genes in obsessive-compulsive disorder. *Psychiatric Genetics, 8*(3), 163-170.

Blum, K., Baron, D., McLaughlin, T. P., Giordano, J., Ceccanti, M. D., & Badgaiyan, R. (2024). Summary document research on RDS anti-addiction modeling: Annotated bibliography. *Journal of Addiction Psychiatry, 8*(1), 1-33.

Blum, K., Braverman, E. R., Holder, J. M., Lubar, J. F., Monastra, V. J., Miller, D., … Comings, D. E. (2000). The reward deficiency syndrome: A biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. *Journal of Psychoactive Drugs, 32*, 1-112. https://doi.org/10.1080/02791072.2000.10736099

Blum, K., Dennen, C. A., Elman, I., Bowirrat, A., Thanos, P. K., Badgaiyan, R. D., … Gold, M. S. (2022). Should reward deficiency syndrome (RDS) be considered an umbrella disorder for mental illness and associated genetic and epigenetic-induced dysregulation of brain reward circuitry? *Journal of Personalized Medicine, 12*(10), 1719. https://doi.org/10.3390/jpm12101719

437 Blum, K., Gold, M., Demetrovics, Z., Archer, T., Thanos, P. K., Baron, D., & Badgaiyan, R. D.
438 (2017). Substance use disorder: A bio-directional subset of reward deficiency syndrome.
439 *Frontiers in Bioscience (Landmark Edition, 22)* (9), 1534-1548. https://doi.org/10.2741/4557

440 Carnes, P. (1991). *Don't call it love: Recovery from sexual addiction.* Bantam Books.

441 Carnes, P., Green, B., & Carnes, S. (2010). The same yet different: Refocusing the Sexual
442 Addiction Screening Test (SAST) to reflect orientation and gender. *Sexual Addiction &*
443 *Compulsivity, 17*(1), 7-30. https://doi.org/10.1080/10720161003604087

444 Comings, D. E., & Blum, K. (2000). Reward deficiency syndrome: Genetic aspects of behavioral
445 disorders. *Progress in Brain Research, 126*, 325-341. https://doi.org/10.1016/S0079-
446 6123(00)26022-6

447 Cornish, K. M., Manly, T., Savage, R., Swanson, J., Morisano, D., Butler, N., … Hollis, C. P.
448 (2005). Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD
449 symptoms and response inhibition in a general population sample. *Molecular Psychiatry, 10*(7),
450 686-698. https://doi.org/10.1038/sj.mp.4001641

451 Doucette-Stamm, L. A., Blakely, D. J., Tian, J., Mockus, S., & Mao, J. I. (1995). Population
452 genetic study of the human dopamine transporter gene (DAT1). *Genetic Epidemiology, 12*(3),
453 303-308. https://doi.org/10.1002/gepi.1370120307

454 Dreher, J. C., Kohn, P., Kolachana, B., Weinberger, D. R., & Berman, K. F. (2009). Variation in
455 dopamine genes influences responsivity of the human reward system. *Proceedings of the*
456 *National Academy of Sciences, 106*(2), 617-622. https://doi.org/10.1073/pnas.0805517106

457 Erblich, J., Lerman, C., Self, D. W., Diaz, G. A., & Bovbjerg, D. H. (2004). Stress-induced
458 cigarette craving: Effects of the *DRD2* TaqI RFLP and *SLC6A3* VNTR polymorphisms.
459 *Pharmacogenomics Journal, 4*(2), 102-109. https://doi.org/10.1038/sj.tpj.6500227

460 Franke, B., & Buitelaar, J. K. (2018). Gene-environment interactions. In *Oxford Textbook of*
461 *Attention Deficit Hyperactivity Disorder* (p. 35).

462 Franklin, T. R., Lohoff, F. W., Wang, Z., Sciortino, N., Harper, D., Li, Y., … Childress, A. R.
463 (2009). *DAT* genotype modulates brain and behavioral responses elicited by cigarette cues.
464 *Neuropsychopharmacology, 34*(3), 717-728. https://doi.org/10.1038/npp.2008.124

465 Giordano, A. L., Hedden, L. E., Kim, S. W., Lundeen, L. A., & Lu, Z. (2024). Childhood trauma
466 and sex addiction among adult men. *Journal of Addictions & Offender Counseling.*
467 https://doi.org/10.1002/jaoc.12134

468 Gondre-Lewis, M. C., Bassey, R., & Blum, K. (2020). Pre-clinical models of reward deficiency
469 syndrome: A behavioral octopus. *Neuroscience & Biobehavioral Reviews, 115*, 164-188.
470 https://doi.org/10.1016/j.neubiorev.2020.04.021

471 Grunblatt, E., Werling, A. M., Roth, A., Romanos, M., & Walitza, S. (2019). Association study
472 and a systematic meta-analysis of the VNTR polymorphism in the 3'-UTR of dopamine
473 transporter gene and attention-deficit hyperactivity disorder. *Journal of Neural Transmission*
474 *(Vienna), 126*(4), 517-529. https://doi.org/10.1007/s00702-019-01998-x

Guo, G., Tong, Y., & Cai, T. (2008). Gene by social context interactions for number of sexual partners among White male youths: Genetics-informed sociology. *American Journal of Sociology, 114*(S1), S36-S66. https://doi.org/10.1086/592207

Guo, G., Tong, Y., Xie, CW., & Lange, L. A. (2007). Dopamine transporter, gender, and number of sexual partners among young adults. *European Journal of Human Genetics, 15*(3), 279-287. https://doi.org/10.1038/sj.ejhg.5201763

Hemmingsa, S. M. J., Kinnear, C. J., Niehaus, D. J. H., Moolman-Smook, J. C., Lochner, C., Knowles, J. A., … Stein, D. J. (2003). Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder. *European Neuropsychopharmacology, 13*(2), 93-98. https://doi.org/10.1016/S0924-977X(02)00129-3

Jiang, S., Wallace, K., Yang, E., Roper, L., Aryal, G., Lee, D., … Aitchison, K. J. (2023). Logistic regression with machine learning sheds light on the problematic sexual behavior phenotype. *Journal of Addiction Medicine, 17*(2), 174-181. https://doi.org/10.1097/ADM.0000000000001078

Jiang, Z., Chen, Z., & Chen, X. (2023). Candidate gene-environment interactions in substance abuse: A systematic review. *PLOS ONE, 18*(10), e0287446. https://doi.org/10.1371/journal.pone.0287446

Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction: A neurocircuitry analysis. *The Lancet Psychiatry, 3*(8), 760-773. https://doi.org/10.1016/S2215-0366(16)00104-8

494 Kraus, S. W., Voon, V., & Potenza, M. N. (2016). Should compulsive sexual behavior be
495 considered an addiction? *Addiction, 111*(12), 2097-2106. https://doi.org/10.1111/add.13297

496 Kuzma, J. M., & Black, D. W. (2008). Epidemiology, prevalence, and natural history of
497 compulsive sexual behavior. *Psychiatric Clinics of North America, 31*(4), 603-611.
498 https://doi.org/10.1016/j.psc.2008.06.005

499 Lahey, B. B., Rathouz, P. J., Lee, S. S., Chronis-Tuscano, A., Pelham, W. E., Waldman, I. D., &
500 Cook, E. H. (2011). Interactions between early parenting and a polymorphism of the child's
501 dopamine transporter gene in predicting future child conduct disorder symptoms. *Journal of*
502 *Abnormal Psychology, 120*(1), 33-45. https://doi.org/10.1037/a0021133

503 Ma, Y., Yuan, W., Cui, W., & Li, M. D. (2016). Meta-analysis reveals significant association of
504 3'-UTR VNTR in SLC6A3 with smoking cessation in Caucasian populations.
505 *Pharmacogenomics Journal, 16*(1), 10-17. https://doi.org/10.1038/tpj.2015.44

506 Reith, M. E. A., Kortagere, S., Wiers, C. E., Sun, H., Kurian, M. A., Galli, A., … Lin, Z. (2022).
507 The dopamine transporter gene *SLC6A3*: Multidisease risks. *Molecular Psychiatry, 27*(2), 1031-
508 1046. https://doi.org/10.1038/s41380-021-01341-5

509 Riemersma, J., & Sytsma, M. (2013). A new generation of sexual addiction. *Sexual Addiction &*
510 *Compulsivity, 20*(4), 306-322. https://doi.org/10.1080/10720162.2013.843067

511 Salatino-Oliveira, A., Rohde, L. A., & Hutz, M. H. (2018). The dopamine transporter role in
512 psychiatric phenotypes. *American Journal of Medical Genetics B: Neuropsychiatric Genetics,*
513 *177*(2), 211-231. https://doi.org/10.1002/ajmg.b.32578

514 Schmidt, C., Morris, L. S., Kvamme, T. L., Hall, P., Birchard, T., & Voon, V. (2017).
515 Compulsive sexual behavior: Prefrontal and limbic volume and interactions. *Human Brain*
516 *Mapping, 38*(3), 1182-1190. https://doi.org/10.1002/hbm.23447

517 Schneider, J. P., & Schneider, B. H. (1996). Couple recovery from sexual addiction/co addiction:
518 Results of a survey of 88 marriages. *Sexual Addiction & Compulsivity: The Journal of Treatment*
519 *and Prevention, 3*(2), 111-126.

520 Šerý O, Paclt I, Drtílková I, Theiner P, Kopečková M, Zvolský P, Balcar VJ. (2015). A 40-bp
521 VNTR polymorphism in the 3'-untranslated region of *DAT1/SLC6A3* is associated with ADHD
522 but not with alcoholism. *Behavioral Brain Functions, 11*, 21. https://doi.org/10.1186/s12993-
523 015-0066-8

524 StataCorp. (2023). *Stata statistical software: Release 17.* StataCorp LLC.

525 Turner, D., Briken, P., Grubbs, J., Malandain, L., Mestre-Bach, G., Potenza, M. N., & Thibaut,
526 F. (2022). The World Federation of Societies of Biological Psychiatry guidelines on the
527 assessment and pharmacological treatment of compulsive sexual behaviour disorder. *Dialogues*
528 *in Clinical Neuroscience, 24*(1), 10-69. https://doi.org/10.1080/19585969.2022.2134739

529 Vandenbergh, D. J., Persico, A. M., Hawkins, A. L., Griffin, C. A., Li, X., Jabs, E. W., & Uhl, G.
530 R. (1992). Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays
531 a VNTR. *Genomics, 14*(4), 1104-1106. https://doi.org/10.1016/s0888-7543(05)80138-7

532 Vandenbergh, D. J., Persico, A. M., & Uhl, G. R. (1992). A human dopamine transporter cDNA
533 predicts reduced glycosylation, displays a novel repetitive element and provides racially-

534 dimorphic TaqI RFLPs. *Brain Research Molecular Brain Research, 15*(1-2), 161-166.
535 https://doi.org/10.1016/0169-328x(92)90165-8

536 Volkow, N. D., Wang, G.-J., Newcorn, J. H., Kollins, S. H., Wigal, T. L., Telang, F., … Logan,
537 J. (2011). Motivation deficit in ADHD is associated with dysfunction of the dopamine reward
538 pathway. *Molecular Psychiatry, 16*(11), 1147-1154. https://doi.org/10.1038/mp.2010.97

539 Walton, M. T., & Bhullar, N. (2018). Compulsive sexual behavior as an impulse control
540 disorder: Awaiting field studies data. *Archives of Sexual Behavior, 47*(5), 1327-1331.
541 https://doi.org/10.1007/s10508-018-1200-0

542 **Figure 1. Forest Plots of Problematic Sexual Behavior (PSB) Logistic Regression Analysis**

543 **in Comparison Participants**



544

545 By logistic regression. The log likelihood of the model was -192.24 (n = 509, with 5 outliers

546 removed, with a pseudo $R^2 = 0.12$, $P<0.001$). The model passed the link test with a significant

547 *P*(hat) (P=0.0080) and a nonsignificant *P*(hatsq) (P=0.66). The probability of the Hosmer-

548 Lemeshow $\chi 2$ test was insignificant (P=0.75), suggesting good model fit. The mean VIF and the

549 condition number were 1.06 and 3.38, respectively. The model accuracy, area under the ROC

550 curve, sensitivity, specificity, and F score were 85.07%, 73.87%, 3.90%, 99.54%, and 0.073,

551 respectively. The exact *P*-values were as follows: family history of PSB ($P=9.19\times10^{-4}$), gender

552 (men: $P=5.17\times10^{-8}$). Power analysis demonstrated that the regression model had a power of over

553 0.90. *Abbreviation: PSB: problematic sexual behavior; SLC6A3: solute carrier family 6 member*

554 *3; VIF: variance inflation factor.*

555

Figure 2. Forest Plots of Problematic Sexual Behavior (PSB) Logistic Regression Analysis in Patients and Comparison Participants Without PSB



By logistic regression. The log likelihood of the model was -195.53 (n=739, after removing outliers, n=105, with 102 having PSB, and with a pseudo R^2=0.58, P<0.001). The model passed the link test with a significant P(hat) (P<0.001) and a nonsignificant P(hatsq) (P=0.56). The probability of the Hosmer-Lemeshow $\chi 2$ test was insignificant (P=0.98), suggesting a good model fit. The mean VIF and the condition number were 1.60 and 4.18, respectively. The model accuracy, area under the ROC curve, sensitivity, specificity, and F score were 85.39%, 94.03%, 70.63%, 95.64%, and 0.80, respectively. The exact P-values were as follows: childhood trauma ($P=8.72\times10^{-11}$), family history of PSB ($P=3.43\times10^{-12}$), and gender (men, $P<2.00\times10^{-16}$). Power analysis demonstrated that the regression model had a power of over 0.90. *Abbreviation: PSB: problematic sexual behavior; SLC6A3: solute carrier family 6 member 3; VIF: variance inflation factor.*

571 **Figure 3. Forest Plot of Reward Deficiency Syndrome (RDS) Logistic Regression Analysis**

572 **in Patients and Comparison Participants**



573

574 By logistic regression. The log likelihood of the model was -624.29 (n=1044, after removed 282

575 outliers, with 91 of them being RDS positive, a pseudo R^2=0.13, P<0.001). The model passed the

576 link test with a significant P(hat) (P<0.001) and a nonsignificant P (hatsq) (P=0.81). The

577 probability of the Hosmer-Lemeshow χ2 test was insignificant (P=0.99), suggesting a good

578 model fit. The mean VIF and the condition number were 2.49 and 10.03, respectively. The model

579 accuracy, area under the ROC curve, sensitivity, specificity, and F score were 68.29%, 72.00%,

580 67.46%, 69.16%, and 0.71, respectively. The exact P-values were as follows: the interaction term

581 of 10/10 genotype and childhood trauma (P=3.68×10^{-4}), the 10/10 genotype of *SLC6A3* 3'

582 VNTR (P=1.73×10^{-4}), self-reported mental health condition(s) (P=1.46×10^{-10}), childhood

583 trauma (P=3.88×10^{-5}) and being PSB patients (P<2.00×10^{-16}). Power analysis demonstrated that

584 the regression model had a power of over 0.90. *Abbreviation: PSB: problematic sexual behavior;*

585 *SLC6A3: solute carrier family 6 member 3; VIF: variance inflation factor*

586 **Table 1. Demographic and Clinical Variables across Subgroups: Scores Indicate Median (Ranges) or Frequencies**

587 **(Percentages)**

Variables		Comparison participants without PSB (n=266-448)	Comparison participants with PSB (n=55-89)	PSB Patients (n=418-434)
Age [a]		23 (18-55) [b]	22 (18-66) [b]	43 (19-80) [c]
Gender [a]	Women	309 (69.8%)	35 (42.2%)	23 (6.3%)
	Men	134 (30.2%)	50 (58.8%)	408 (94.7%)
SLC6A3 genotype, *P*=0.100	9/9 and 9/10	210 (46.9%)	35 (39.3%)	209 (48.2%)
	10/10	228 (50.9%)	54 (60.7%)	209 (48.2%)
	Rare	10 (2.2%)	0 (0%)	16 (3.6%)
Problematic Sexual Behavior - adjusted SAST-R core [a]		0 (0-5) [b]	7 (4-18) [c]	15 (10-18) [d]
Relationship disturbance [a]		0 (0-2) [b]	1 (0-4) [c]	4 (0-4) [d]
Loss of control [a]		0 (0-2) [b]	2 (0-4) [c]	4 (0-4) [d]
Preoccupation [a]		0 (0-3) [b]	1 (0-4) [c]	2 (0-4) [d]

Variables	Comparison participants without PSB (n=266-448)	Comparison participants with PSB (n=55-89)	PSB Patients (n=418-434)
Affect disturbance [a]	0 (0-3) [b]	3 (1-5) [c]	4 (2-5) [d]
Reward deficiency syndrome a	0 (0%)	60 (67.4%)	318(84.1%)
FTND [a]	0 (0-1) [b]	0 (0-7) [c]	0 (0-12) [c]
DPGDF (P=0.051)	0 (0-3) [b]	0 (0-9) [c]	0 (0-9) [c]
SA-SAPAS [a]	1 (0-3) [b]	1 (0-8) [c]	2 (0-8) [d]
ASRS [a]	1 (0-3) [b]	3 (0-6) [c]	3 (0-6) [c]
RCBS [a]	10 (6-24) [b]	11 (6-40) [c]	11 (6-42) [c]
IAT [a]	22 (0-30) [b]	30 (0-62) [c]	38 (0-97) [d]
Childhood trauma [a]	67 (15.1%)	33 (37.1%)	290 (70.9%)
Self-reported mental health condition(s) [a]	0 (0%)	24 (27.0%)	277 (65.2%)
Number of self-reported mental health condition(s) [a]	0 [b]	0 (0-12) [c]	1 (0-9) [d]

Variables	Comparison participants without PSB (n=266-448)	Comparison participants with PSB (n=55-89)	PSB Patients (n=418-434)
Number of mental health condition(s) in family history [a]	3 (0-17) [b]	4 (0-17) [c]	6 (0-24) [d]
Family history of PSB [a]	17 (3.8%)	19 (21.6)	273 (62.8%)
OCD [a]	0 (0%)	8 (9.0%)	61 (14.1%)

588

589 [a]: significant omnibus effect (P<0.001);

590 [b,c,d]: different superscripts denote significant differences ($P < 0.05$) between groups

591

592 Kruskal-Wallis H test and Dunn's post-hoc tests for continuous variables; Pearson's or Fisher's χ^2 test (cells < 5) for categorical

593 variables; Abbreviations: *PSB: problematic sexual behavior; SAST-R: Sexual Addiction Screening Test-Revised; ASRS: Adult ADHD*

594 *Self-Report Scale version 1.1; FTND: Fagerström Test for Nicotine Dependence; IAT: Internet Addiction Test; OCD: obsessive-*

595 *compulsive disorder; RCBS: Richmond Compulsive Buying Scale*

596

597

598 **Table 2. Distribution of Demographic and Clinical Variables by *Solute Carrier Family 6 Member 3 (SLC6A3)* Genotypic**

599 **Group: Scores Indicate Median (Ranges) or Frequencies (Percentages)**

Variables	Comparison participants (n= 55-89 with PSB; n=266-438 without PSB)		PSB patients (391-418) and comparison participants without PSB (n=266-438)		
	9/9 and 9/10 genotypes)	10/10 genotype	9/9 and 9/10 genotypes	10/10 genotype	Rare genotypes
PSB	*30 (12.2%)* [a]	*52 (18.4%)* [a]	200 (48.1%)	202 (46.1%)	16 (61.5%)
Adjusted SAST-R core	1 (0-14)	1 (0-18)	4.5 (0-18)	3 (0-18)	12.5 (0-18)
Relationship disturbance	0 (0-3)	0 (0-4)	3 (0-4)	3 (0-4)	3 (0-4)
Loss of control	0 (0-4)	0 (0-4)	2 (0-4)	1 (0-4)	3 (0-4)
Preoccupation	0 (0-4)	0 (0-4)	1 (0-4)	1 (0-4)	1.5 (0-4)
Affect disturbance	0 (0-4)	0 (0-5)	2 (0-5)	2 (0-5)	4 (0-5)
Reward deficiency syndrome	*21 (8.6%)* [a]	*39 (13.8%)* [a]	155 (38.3%)	152 (36.4%)	11(45.8%)
FTND	0 (0-4)	0 (0-7)	0 (0-12)	0 (0-11)	0 (0-4)
DPGDF	0 (0-9)	0 (0-9)	0 (0-8)	0 (0-9)	0 (0-3)

Variables	Comparison participants (n= 55-89 with PSB; n=266-438 without PSB)		PSB patients (391-418) and comparison participants without PSB (n=266-438)		
	9/9 and 9/10 genotypes)	**10/10 genotype**	**9/9 and 9/10 genotypes**	**10/10 genotype**	**Rare genotypes**
SA-SAPAS	1 (0-7)	1 (0-8)	1 (0-8)	1 (0-8)	1 (0-6)
ASRS	**1 (0-6)** [b]	**1 (0-6)** [b]	2 (0-6)	2 (0-6)	1 (0-6)
RCBS	**10 (6-30)** [b]	**10 (6-40)** [b]	10 (6-32)	10 (6-32)	10 (6-42)
IAT	**22 (0-55)** [b]	**24 (2-62)** [b]	25 (0-89)	26 (1-97)	28 (4-88)
Childhood trauma	45 (18.4%)	55 (19.7%)	169 (41.7%)	176 (41.7%)	12 (46.1%)
Self-reported mental health condition(s)	*7 (2.9%)* [a]	*17 (6.0%)* [a]	131 (31.7%)	134 (30.9%)	12 (48.0%)
Number of self-reported mental health condition(s)	*0 (0-10)* [a]	*0 (0-12)* [a]	0 (0-6)	0 (0-9)	0 (0-9)
Number of mental health condition(s) in family history	3 (0-17)	3 (0-17)	4 (0-24)	4 (0-19)	4.5 (0-14)
Family history of PSB	15 (6.1%)	21 (7.5%)	142 (33.9%)	138 (31.6%)	10 (38.5%)

Variables	Comparison participants (n= 55-89 with PSB; n=266-438 without PSB)		PSB patients (391-418) and comparison participants without PSB (n=266-438)		
	9/9 and 9/10 genotypes)	**10/10 genotype**	**9/9 and 9/10 genotypes**	**10/10 genotype**	**Rare genotypes**
OCD	3 (1.2%)	5 (1.8%)	**27 (6.5%)** [b]	**29 (6.6%)** [b]	**5 (19.2%)** [b]

[a]: *P<0.1;*

[b]: ***P*<0.05**

Mann-Whitney *U* test for two-group comparisons of continuous variables; Kruskal-Wallis *H* test and Dunn's post-hoc tests for three-group comparisons of continuous variables; Pearson's or Fisher's χ^2 test (cells < 5) for categorical variables; Abbreviations: *PSB: problematic sexual behavior; SAST-R: Sexual Addiction Screening Test-Revised; ASRS: Adult ADHD Self-Report Scale version 1.1; FTND: Fagerström Test for Nicotine Dependence; IAT: Internet Addiction Test; OCD: obsessive-compulsive disorder; RCBS: Richmond Compulsive Buying Scale*